Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2002

View Archived Issues

Development of clinical-stage anticancer drug stopped

Cepharanoline derivative identified with potent and selective activity against HIV-1

Long-term statin therapy for improving outcome following myocardial infarction

Addition of spironolactone to ACE inhibition improves endothelial vasomotor dysfunction in CHF

Another Roche product approved in the E.U.

Antiangiogenic effects demonstrated for CA4P in mouse model of proliferative retinopathy

Two studies highlight efficacy of Elidel in head and neck eczema

Phase IIa trial of TA-CD for cocaine addiction begins

Combination of Androsorb and Estrasorb examined in hormone-deficient women

Positive initial efficacy data from MethyPatch phase III trial in ADHD

Marketing clearance sought for Aldurazyme in Europe

Synaptic enters collaborations with Gruenenthal and Kissei

New dose of Concerta approved by FDA

BTG acquires ophthalmic drug delivery insert technology

Phase II study of Femprox in FSAD completed

Genzyme Molecular Oncology licenses rights to gene associated with colon cancer metastasis

MediGene signs ionizing radiation research agreement with U. of Chicago

AlgoRx completes acquisition of PowderJect's drug business

FluINsure influenza vaccine meets immune response endpoints in phase I trial

Cathepsin S inhibitors in development at Ortho-McNeil

Boehringer Ingelheim presents heterocyclic tyrosine kinase inhibitors

Roche patent covers new inhibitors of lanosterol synthase and their potential uses

Antitumor camptothecin esters reported by California center

Novel peptides inhibit interaction of Abeta with alpha7 nicotinic receptors

Tufts patents tetracycline-based antibacterials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...